Abstract
Black individuals with heart failure (HF) appear to obtain a greater benefit in reducing the risk of hospitalization for heart failure (HHF) from SGLT2 inhibitors (SGLT2i) and less benefit for mortality from beta-blockers compared to their White counterparts. This meta-analysis of 19 randomized controlled trials (RCTs) involving over 40,000 patients highlights significant racial disparities in pharmacological treatment efficacy.
Introduction
Heart failure is a global health crisis with a disproportionate impact on Black populations, who face higher prevalence, earlier onset, and increased rates of hospitalization and death. Despite these disparities, Black patients have historically been underrepresented in the RCTs that establish standard-of-care guidelines. This study addresses the critical knowledge gap regarding whether standard pharmacological therapies perform uniformly across Black and White populations.
Methods
Following PRISMA guidelines, researchers conducted a systematic review of major databases (Medline, Embase, Cochrane CENTRAL) for RCTs involving adults with HF that provided race-specific outcome data. Primary outcomes included all-cause death, hospitalization for heart failure (HHF), and a composite of cardiovascular death or HHF. Pooled Risk Ratios (RR) were calculated using random-effects models, with a specific focus on interaction effects ($P_{interaction}$) to identify statistically significant differences in drug impact based on race.
Datasets
The analysis synthesized data from 19 RCTs, encompassing 40,287 participants. While the total pool was large, only 3,489 (8.6%) were Black participants, compared to 36,798 White participants. Notable trials included DELIVER, DAPA-HF, PARADIGM-HF, and MERIT-HF.
Key Results
The meta-analysis revealed two major divergent outcomes between racial groups:
- SGLT2 inhibitors (HHF): Black patients experienced a 61% reduction in HHF risk (RR 0.39, 95% CI 0.19–0.80), significantly outperforming the 10% reduction seen in White patients (RR 0.90, 95% CI 0.71–1.14; $P_{interaction} = 0.030$).
- Beta-blockers (All-cause death): White patients saw a robust 35% reduction in mortality (RR 0.65, 95% CI 0.52–0.81). However, no significant mortality reduction was observed for Black patients (RR 1.14, 95% CI 0.88–1.47; $P_{interaction} = 0.001$).
For other mainstay therapies, such as ACE inhibitors and ARNi (sacubitril/valsartan), treatment effects were generally consistent across both racial groups.
Discussion and Physiological Hypotheses
The authors propose several mechanisms for these disparities:
- Natriuresis and SGLT2i: Black individuals often exhibit lower natriuretic peptide levels and higher salt sensitivity. The sodium-excreting (natriuretic) effect of SGLT2i may more effectively address this specific physiological profile.
- Beta-receptor Responsiveness: The reduced efficacy of beta-blockers in Black populations may be linked to genetic polymorphisms (e.g., in the ADRB1 gene) and lower baseline renin levels, potentially making beta-receptors less responsive to inhibition.
Limitations
The study is limited by the broad categorization of "Black" and "White," which masks significant internal genetic and socioeconomic diversity. Additionally, some subgroup analyses were limited by a small number of trials, and the study did not differentiate between HF phenotypes (HFrEF vs. HFpEF).
Conclusion
These findings underscore the necessity for inclusive clinical trial design and suggest that a "one-size-fits-all" approach to HF pharmacology may overlook critical racial differences in treatment response. Further mechanistic research is required to optimize personalized care for diverse patient populations.
Summary updated